LUMAKRAS Drug Patent Profile

Which patents cover Lumakras, and what generic alternatives are available?

Lumakras is a drug marketed by Amgen Inc and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and eighty-five patent family members in thirty-nine countries.

The generic ingredient in LUMAKRAS is sotorasib. One supplier is listed for this compound. Additional details are available on the sotorasib profile page.

DrugPatentWatch^® Generic Entry Outlook for Lumakras

Lumakras was eligible for patent challenges on May 28, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 21, 2038. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for LUMAKRAS

International Patents:	185
US Patents:	6
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for LUMAKRAS

LUMAKRAS is protected by ten US patents and five FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,519,146.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-002	Jan 20, 2023		RX	Yes	Yes
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-003	Jun 26, 2024		RX	Yes	No
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-002	Jan 20, 2023		RX	Yes	Yes	12,280,056
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-002	Jan 20, 2023		RX	Yes	Yes	11,426,404
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-001	May 28, 2021		RX	Yes	No	11,426,404
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-003	Jun 26, 2024		RX	Yes	No	11,426,404
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-003	Jun 26, 2024		RX	Yes	No	10,519,146		Y	Y

International Patents for LUMAKRAS

When does loss-of-exclusivity occur for LUMAKRAS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

San Marino

Saudi Arabia

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LUMAKRAS around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	111882
Argentina	122783
Argentina	122784
Argentina	122785
Argentina	122786
Argentina	122787
Argentina	122788

Investment Scenario, Market Dynamics, and Financial Trajectory for LUMAKRAS (Sotorasib)

Last updated: February 3, 2026

Summary

LUMAKRAS (sotorasib) is a targeted oncology therapy developed by Amgen, approved by the FDA in May 2021 for treating KRAS G12C-mutated non-small cell lung cancer (NSCLC). As a first-in-class KRAS G12C inhibitor, LUMAKRAS has disrupted a historically "undruggable" mutation, presenting significant commercial potential. This report analyzes the current market landscape, growth drivers, competitive environment, financial projections, and investment risks associated with LUMAKRAS over the next five years.

---

1. Market Overview and Key Drivers

1.1 Market Size and Growth Projections

Parameter	Value/Estimate	Source
Global NSCLC market (2023)	~$23 billion	GlobalData[1]
KRAS-mutant NSCLC prevalence (2023)	~12-15% of all NSCLC cases	CDC & WHO[2], [3]
Addressable patient population (2023)	Estimated 150,000–200,000 globally	Cancer registries
Expected CAGR (2023–2028)	8-10%	IQVIA[4]

1.2 Key Market Drivers

• Unmet Medical Need: KRAS G12C mutations observed in 13–15% of NSCLC cases, with limited targeted therapies prior to LUMAKRAS.
• Regulatory Approvals: FDA approval in May 2021; EMA and other major markets approval follow.
• Expanding Indications: Ongoing trials exploring LUMAKRAS in colorectal, pancreatic, and other solid tumors.
• Combination Therapies: Trials combining LUMAKRAS with immunotherapies, increasing potential patient segments.
• Market Penetration: Growing adoption driven by clinical guidelines and reimbursement policies.

---

2. Competitive Landscape

2.1 Major Competitors

Drug Name	Developer	Approval Status	Mechanism	Notes
LUMAKRAS (sotorasib)	Amgen	FDA approved (2021)	KRAS G12C inhibitor	First-mover in KRAS G12C
Adagrasib (MRTX849)	Mirati Therapeutics	FDA Breakthrough Therapy 2021	KRAS G12C inhibitor	Pending approval, undergoing trials
JDQ443	Jazz Pharmaceuticals	In clinical trials	KRAS G12C inhibitor	Early-stage development
Other emerging agents	Multiple biotech firms	Preclinical/clinical stages	KRAS G12C targeting	Intensifying competition

2.2 Market Share and Differentiation

Parameter	LUMAKRAS	Competitors
Market penetration (2023–2025 forecast)	20–30% of KRAS G12C NSCLC patients within 2 years	Expected to gain significant share as first approved
Differentiating features	First-in-class approval, established safety profile	Pending approvals, novel trial data

---

3. Regulatory and Reimbursement Environment

Region	Status	Implications
USA	Approved (FDA, May 2021)	Immediate market access, strong reimbursement
Europe	Approved (EMA, late 2021)	Facilitates European sales, slower uptake
Japan and Asia-Pacific	Approved in Japan (2022), expanding	Growth potential in high prevalence regions
Reimbursement Policies	Favorable in developed countries	Encourages adoption, influences sales revenue

---

4. Financial Trajectory and Revenue Projections

4.1 Revenue Model Assumptions (2023–2028)

Parameter	2023	2024	2025	2026	2027	2028	Source/Notes
Total Addressable Market (TAM)	$2.5B	$3.2B	$4.0B	$4.9B	$6.0B	$7.2B	Growth driven by expansion & uptake
Market Penetration (KRAS NSCLC)	15% of TAM	20%	25%	30%	35%	40%	Due to increasing awareness & approval
Pricing (average annual per patient)	$80,000 – $120,000	Consistent	Slight increase	Slight increase	Slight increase	Slight increase	Based on current pricing and discounts
Patient Uptake (patients/year)	20,000	40,000	60,000	80,000	100,000	120,000	Growing with indication expansion

4.2 Revenue Forecast Table

Year	Estimated Sales Revenue (USD)	Notes
2023	~$600 million to $900 million	Launch year, initial adoption
2024	~$1.2 billion to $1.5 billion	Increasing market penetration
2025	~$1.8 billion to $2.2 billion	Expanded indications and access
2026	~$2.4 billion to $2.8 billion	Stable growth with competitive entry
2027	~$3.0 billion to $3.5 billion	Global expansion, combo trials
2028	~$3.6 billion to $4.2 billion	Mature market, new indications

4.3 Cost and Profitability Considerations

• R&D and Commercialization Costs: Estimated at 30–40% of sales in initial years, decreasing as market matures.
• Pricing Strategy: Premium pricing justified by targeted therapy status, yet subject to negotiations and health payer restrictions.
• Margins: Anticipated gross margin of 70–80% post-commercial scaling.

---

5. Investment Risks and Challenges

5.1 Market Entry and Competition Risks

Risk Factor	Impact	Mitigation Strategy
Emerging competitors (e.g., adagrasib)	Market share erosion	Robust clinical pipeline, post-market expansion
Delayed approval in new territories	Revenue delays	Regulatory engagement, early submission
Off-target effects and safety issues	Regulatory hurdles	Vigilant post-market surveillance

5.2 Regulatory and Reimbursement Risks

Risk Factor	Impact	Mitigation Strategy
Stringent pricing negotiations	Revenue stagnation or reduction	Value-based pricing, demonstrating clinical benefit
Reimbursement restrictions	Limited prescription access	Engagement with payers, demonstration of cost-effectiveness

5.3 Technical and Clinical Risks

Risk Factor	Impact	Mitigation Strategy
Resistance mutations developing	Reduced long-term efficacy	Combination therapies and next-gen inhibitors
Limited data on expanded indications	Delays in indication approvals	Ongoing and robust clinical trial programs

---

6. Comparative Analysis and Strategic Insights

6.1 Key Differentiators

Feature	LUMAKRAS	Competitors
First-mover advantage	Yes	No
Clinical efficacy	ORR ~37% (per clinical trial data)	Similar, but with ongoing data
Approved indications	NSCLC (G12C mutation)	G12C NSCLC only
Pricing	~$80,000–$120,000/year	Similar or higher depending on market

6.2 Investment Recommendations

• Growth Potential: High due to first-mover status, expanding indications, and pipeline development.
• Risk Factors: Competition from emerging agents, regulatory delays, resistance development.
• Portfolio Positioning: Suitable for investors targeting targeted cancer therapies with significant market potential.

---

7. Key Takeaways

• Market Validation: LUMAKRAS is the first approved KRAS G12C inhibitor, capturing initial market share in an underserved segment of NSCLC.
• Growth Trajectory: Expected to reach ~$4 billion in sales by 2028, driven by increased adoption, expanded indications, and combination strategies.
• Competitive Edge: First-mover advantage and strong clinical data position LUMAKRAS favorably against emerging competitors.
• Risks: Market penetration depends on regulatory approvals, payer coverage, and competitively advancing pipeline agents.
• Strategic Outlook: Amgen’s continued investment in combination therapies and global expansion are critical to sustaining revenue growth.

---

FAQs

Q1: How does LUMAKRAS compare to other targeted lung cancer therapies?
LUMAKRAS is unique as the first FDA-approved KRAS G12C inhibitor. Its clinical efficacy is comparable to other targeted therapies like EGFR inhibitors, with ORRs around 37%, and it offers a novel mechanism for patients with limited options. Its first-mover advantage provides early market capture potential.

Q2: What are the primary factors influencing LUMAKRAS's market growth?
Key factors include expansion into additional tumor types, regulatory approvals in major markets, reimbursement policies, clinical trial successes, and successful management of resistance mechanisms via combination therapies.

Q3: What risks could impede LUMAKRAS's financial success?
Potential risks include the emergence of competitors with better efficacy or safety profiles, regulatory delays, resistance development, restricted payer coverage, and manufacturing or supply chain challenges.

Q4: What is the current pipeline status for LUMAKRAS?
Amgen is exploring LUMAKRAS in multiple indications beyond NSCLC, including colorectal and pancreatic cancers, and in combination with immunotherapies to widen its therapeutic landscape.

Q5: How do regulatory decisions in key markets affect financial forecasts?
Regulatory approvals significantly influence revenue projections; delays or refusals can defer sales and impact investor confidence. Conversely, swift approvals and reimbursement agreements accelerate market penetration and revenue realization.

---

References

[1] GlobalData. (2023). Lung Cancer Market Report.
[2] CDC. (2022). Lung Cancer Statistics.
[3] WHO. (2022). Cancer Data.
[4] IQVIA. (2023). Pharmaceutical Market Trends.